Research Paper Volume 13, Issue 23 pp 25518—25549
Identification of a novel immune signature for optimizing prognosis and treatment prediction in colorectal cancer
Figure 5. The immunotherapeutic benefit of the IRGs-based risk score in immunotherapeutic treatment cohorts. (A–D) Comparison of AUC values between IRGs-based signature and other eight previous published immune related signatures in four immunotherapeutic datasets. (E) Similarity comparison between IRGs-based signature and other seven previous signatures. (F) SubMap analysis utilizing six immunotherapy datasets. Kaplan-Meier survival curve of OS for patients with high- and low- risk score subtypes for (G) Van Allen et al. (2015) dataset, (H) Hugo et al. (2016) dataset, (I) IMvigor210 dataset, and (J) Snyder et al. (2017) dataset. Bar graph illustrated the treatment response to immunotherapy within high- and low- risk score subtypes in (K) Van Allen et al. (2015) dataset, (L) Hugo et al. (2016) dataset, (M) IMvigor210 dataset, and (N) Snyder et al. (2017) dataset. Violin plots illustrated the distribution of risk score for patients with different immunotherapy responses in (O) Van Allen et al. (2015) dataset, (P) Hugo et al. (2016) dataset, (Q) IMvigor210 dataset, and (R) Snyder et al. (2017) dataset.